Sippican Capital Advisors Apellis Pharmaceuticals, Inc. Transaction History
Sippican Capital Advisors
- $126 Million
- Q4 2024
A detailed history of Sippican Capital Advisors transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Sippican Capital Advisors holds 20,753 shares of APLS stock, worth $511,768. This represents 0.52% of its overall portfolio holdings.
Number of Shares
20,753
Previous 30,313
31.54%
Holding current value
$511,768
Previous $874,000
24.26%
% of portfolio
0.52%
Previous 0.67%
Shares
10 transactions
Others Institutions Holding APLS
# of Institutions
302Shares Held
123MCall Options Held
2.63MPut Options Held
845K-
Avoro Capital Advisors LLC New York, NY12.2MShares$301 Million5.68% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$293 Million17.73% of portfolio
-
Wellington Management Group LLP Boston, MA11.8MShares$291 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$248 Million0.01% of portfolio
-
Morgan Stanley New York, NY9.63MShares$237 Million0.02% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.71B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...